Lv54
1080 积分 2024-03-29 加入
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma
5天前
已完结
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
7天前
已完结
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605
9天前
已完结
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial
15天前
已完结
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02
18天前
已完结
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
20天前
已完结
The next generation of immunotherapies for lung cancers
23天前
已完结
First-Line Therapy For Advanced Non–Clear Cell Renal Cell Carcinoma
23天前
已完结
Prostate cancer
26天前
已完结
HER2 testing: evolution and update for a companion diagnostic assay
27天前
已完结
皖公网安备34019202002308
